Elmind Capital, Lp

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$352.2M
Q ending 2026-03-31
Prior quarter
$338.9M
Q ending 2025-12-31
Change
+3.9% QoQ
Positions
34
reported holdings

Largest positions

All 34 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
Cogent Biosciences IncCOGTShares$45.1M1.2M
Syndax Pharmaceuticals IncSNDXShares$43.3M1.9M
Celldex Therapeutics Inc NewCLDXShares$27.4M865K
Cytomx Therapeutics Inc.CTMXShares$21.4M4.5M
Kalvista Pharmaceuticals Inc4XC1Shares$20.6M1.0M
Cg Oncology IncCGONShares$19.7M292K
Vera Therapeutics IncVERAShares$19.4M483K
Vaxcyte IncPCVXShares$18.4M317K
Pharvaris N VShares$13.4M476K
Tyra Biosciences IncTYRAShares$13.4M350K
Beam Therapeutics IncBEAMShares$11.4M476K
Viridian Therapeutics IncVRDNShares$10.5M535K
Biocryst Pharmaceuticals IncBCRXShares$9.5M1.0M
United Therapeutics Corp DelUTHRShares$8.9M15K
Cullinan Therapeutics IncCGEMShares$7.5M530K
Nurix Therapeutics IncNRIXShares$7.1M460K
Mbx Biosciences IncMBXShares$6.3M211K
Krystal Biotech IncKRYSShares$5.7M22K
Dbv Technologies S ADBVTShares$5.5M265K
Relay Therapeutics IncRLAYShares$5.3M537K
Travere Therapeutics IncTVTXShares$5.3M178K
Protagonist Therapeutics IncPTGXShares$4.0M38K
Urogen Pharma LtdShares$4.0M220K
Alumis IncALMSShares$2.9M130K
Biomarin Pharmaceutical IncBMRNShares$2.7M47K
Design Therapeutics IncDSGNShares$2.2M208K
Apellis Pharmaceuticals IncAPLSShares$2.0M50K
Alector IncALECShares$1.9M900K
Immunocore Hldgs PlcIMCRShares$1.8M58K
Amylyx Pharmaceuticals IncAMLXShares$1.6M112K
Engene Holdings IncShares$1.4M210K
Wave Life Sciences LtdShares$1.3M178K
Supernus PharmaceuticalsSUPNShares$1.0M20K
Edgewise Therapeutics IncEWTXShares$315K10K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.